2022
Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
Dijk SW, Krijkamp EM, Kunst N, Gross CP, Wong JB, Hunink MGM. Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials. Value In Health 2022, 25: 1268-1280. PMID: 35490085, PMCID: PMC9045876, DOI: 10.1016/j.jval.2022.03.016.Peer-Reviewed Original ResearchConceptsCohort state-transition modelUS healthcare perspectiveValue of informationFace of uncertaintyQALY willingnessPolicy makersLifetime horizonHealthcare perspectiveState transition modelInformation analysisImmediate approvalModel outcomesImplementation decisionsOptimal momentWillingnessPolicyMakersMost valueCOVID-19DecisionsCostHorizonFurther researchAdditional evidenceUncertainty
2021
Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers
Jongeneel G, Greuter M, Kunst N, van Erning F, Koopman M, Medema J, Vermeulen L, Ijzermans J, Vink G, Punt C, Coupé V. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1726-1734. PMID: 34162659, PMCID: PMC7611620, DOI: 10.1158/1055-9965.epi-21-0078.Peer-Reviewed Original ResearchMeSH KeywordsChemotherapy, AdjuvantColonic NeoplasmsCost-Benefit AnalysisHumansMarkov ChainsNeoplasm StagingNetherlandsQuality-Adjusted Life YearsRisk AssessmentConceptsConsensus molecular subtypesStage II colon cancerGuideline strategyEarly cost-effectiveness analysisColon cancer deathsPrognostic molecular markersMarkov cohort modelDutch societal perspectiveCancer treatment selectionCost-effectiveness analysisAdjuvant chemotherapyAdjuvant treatmentCancer deathCost-effectiveness assessmentMolecular subtypesTreatment selectionCurrent evidenceColon cancerSocietal perspectiveDecision uncertaintyMolecular markersCohort modelPatientsMarkersVOI analysis
2020
Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer
Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAdultAgedAnthracyclinesAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicBreast NeoplasmsCase-Control StudiesCost-Benefit AnalysisCross-Linking ReagentsDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMiddle AgedNeoadjuvant TherapyPaclitaxelQuality-Adjusted Life YearsReceptor, ErbB-2TrastuzumabTubulin ModulatorsUnited StatesConceptsErbB2-positive breast cancerAdjuvant treatment strategiesAdjuvant T-DM1Pathologic complete responseT-DM1Treatment strategiesBreast cancerKATHERINE trialResidual diseaseNeoadjuvant regimenHigher health benefitsHealth care payer perspectiveAdjuvant trastuzumab emtansineAnthracycline/cyclophosphamideDifferent adjuvant therapiesFlatiron Health databaseIncremental cost-effectiveness ratioNeoadjuvant treatment optionsHealth benefitsPositive breast cancerCare payer perspectiveCost-effectiveness ratioBase-case analysisDecision analytic modelH. PatientsPerspective and Costing in Cost-Effectiveness Analysis, 1974–2018
Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018. PharmacoEconomics 2020, 38: 1135-1145. PMID: 32696192, PMCID: PMC7373843, DOI: 10.1007/s40273-020-00942-2.Peer-Reviewed Original Research